Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Gunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Thomas Karn, Tobias Meissner, Karsten E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
The Lancet. Oncology
|
May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
NPJ Breast Cancer
|
June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
Bruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Gunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Thomas Karn, Tobias Meissner, Karsten E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
T Karn, C Denkert, K E Weber, et al.
The Lancet. Oncology
|
May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
NPJ Breast Cancer
|
June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
Bruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Page
of 6